Immunotherapy for recurrent or metastatic head and neck squamous cell carcinoma

2022-01-24

touchPANEL DISCUSSION for touchONCOLOGY Listen to three experts as they explore key clinical considerations when using immune checkpoint inhibitors to treat recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The discussion includes the current role of immune checkpoint inhibitors, factors that may inform treatment decisions and approaches for managing side effects associated with immune checkpoint inhibitors.The experts Prof. Kevin Harrington – The Institute of Cancer Research, London, UK

touchPANEL DISCUSSION for touchONCOLOGY

Listen to three experts as they explore key clinical considerations when using immune checkpoint inhibitors to treat recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The discussion includes the current role of immune checkpoint inhibitors, factors that may inform treatment decisions and approaches for managing side effects associated with immune checkpoint inhibitors.

The experts

Prof. Kevin Harrington – The Institute of Cancer Research, London, UK
Prof. Barbara Burtness – Yale Cancer Center, New Haven, CT, USA
Prof. Jean-Pascal Machiels – Department of Medical Oncology, Cliniques Universitaire St-Luc, Brussels, Belgium

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Merck and Co., Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/immunotherapy-rmhnscc-practical-considerations/

Comments (3)